THE  ||| S:0 E:4 ||| DT
SEARCH  ||| S:4 E:11 ||| NNP
OF  ||| S:11 E:14 ||| IN
COMPOUNDS  ||| S:14 E:24 ||| NNP
WITH  ||| S:24 E:29 ||| NNP
ANTIAGGREGATION  ||| S:29 E:45 ||| NNP
ACTIVITY  ||| S:45 E:54 ||| NNP
AMONG  ||| S:54 E:60 ||| IN
S-ESTERS  ||| S:60 E:69 ||| JJ
OF  ||| S:69 E:72 ||| IN
THIOSULFONIC  ||| S:72 E:85 ||| NNP
ACIDS  ||| S:85 E:91 ||| NNP
According  ||| S:91 E:101 ||| VBG
to  ||| S:101 E:104 ||| TO
the  ||| S:104 E:108 ||| DT
current  ||| S:108 E:116 ||| JJ
understanding ||| S:116 E:129 ||| NN
,  ||| S:129 E:131 ||| ,
the  ||| S:131 E:135 ||| DT
hyperactivation  ||| S:135 E:151 ||| NN
of  ||| S:151 E:154 ||| IN
platelets  ||| S:154 E:164 ||| NNS
may  ||| S:164 E:168 ||| MD
lead  ||| S:168 E:173 ||| VB
to  ||| S:173 E:176 ||| TO
increased  ||| S:176 E:186 ||| VB
intravascular  ||| S:186 E:200 ||| JJ
coagulation  ||| S:200 E:212 ||| NN
and  ||| S:212 E:216 ||| CC
thrombosis ||| S:216 E:226 ||| NN
.  ||| S:226 E:228 ||| .
Today  ||| S:228 E:234 ||| NN
a  ||| S:234 E:236 ||| DT
relevant  ||| S:236 E:245 ||| JJ
issue  ||| S:245 E:251 ||| NN
is  ||| S:251 E:254 ||| VBZ
the  ||| S:254 E:258 ||| DT
search  ||| S:258 E:265 ||| NN
for  ||| S:265 E:269 ||| IN
new  ||| S:269 E:273 ||| JJ
anti-thrombotic  ||| S:273 E:289 ||| JJ
agents  ||| S:289 E:296 ||| NNS
that  ||| S:296 E:301 ||| WDT
are  ||| S:301 E:305 ||| VBP
able  ||| S:305 E:310 ||| JJ
to  ||| S:310 E:313 ||| TO
modulate  ||| S:313 E:322 ||| VB
the  ||| S:322 E:326 ||| DT
activity  ||| S:326 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
platelet  ||| S:338 E:347 ||| JJ
receptors ||| S:347 E:356 ||| NNS
,  ||| S:356 E:358 ||| ,
thus ||| S:358 E:362 ||| RB
,  ||| S:362 E:364 ||| ,
influence  ||| S:364 E:374 ||| VB
the  ||| S:374 E:378 ||| DT
processes  ||| S:378 E:388 ||| NNS
of  ||| S:388 E:391 ||| IN
activation  ||| S:391 E:402 ||| NN
and  ||| S:402 E:406 ||| CC
aggregation  ||| S:406 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
platelets ||| S:421 E:430 ||| NN
.  ||| S:430 E:432 ||| .
The  ||| S:432 E:436 ||| DT
aim  ||| S:436 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
this  ||| S:443 E:448 ||| DT
study  ||| S:448 E:454 ||| NN
was  ||| S:454 E:458 ||| VBD
to  ||| S:458 E:461 ||| TO
investigate  ||| S:461 E:473 ||| VB
the  ||| S:473 E:477 ||| DT
effects  ||| S:477 E:485 ||| NNS
of  ||| S:485 E:488 ||| IN
newly  ||| S:488 E:494 ||| RB
synthesized  ||| S:494 E:506 ||| JJ
thiosulfonate  ||| S:506 E:520 ||| JJ
derivatives  ||| S:520 E:532 ||| NNS
on  ||| S:532 E:535 ||| IN
platelet  ||| S:535 E:544 ||| JJ
aggregation ||| S:544 E:555 ||| NN
.  ||| S:555 E:557 ||| .
The  ||| S:557 E:561 ||| DT
activity  ||| S:561 E:570 ||| NN
of  ||| S:570 E:573 ||| IN
the  ||| S:573 E:577 ||| DT
compounds  ||| S:577 E:587 ||| NN
was  ||| S:587 E:591 ||| VBD
tested  ||| S:591 E:598 ||| VBN
in  ||| S:598 E:601 ||| IN
vitro  ||| S:601 E:607 ||| NNS
using  ||| S:607 E:613 ||| VBG
platelet-rich  ||| S:613 E:627 ||| JJ
plasma ||| S:627 E:633 ||| NN
.  ||| S:633 E:635 ||| .
As  ||| S:635 E:638 ||| IN
a  ||| S:638 E:640 ||| DT
result  ||| S:640 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
the  ||| S:650 E:654 ||| DT
screening  ||| S:654 E:664 ||| NN
test ||| S:664 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
structural  ||| S:670 E:681 ||| JJ
formulas  ||| S:681 E:690 ||| NNS
of  ||| S:690 E:693 ||| IN
four  ||| S:693 E:698 ||| CD
agents  ||| S:698 E:705 ||| NNS
with  ||| S:705 E:710 ||| IN
high  ||| S:710 E:715 ||| JJ
antiaggregative  ||| S:715 E:731 ||| JJ
activity  ||| S:731 E:740 ||| NN
were  ||| S:740 E:745 ||| VBD
established ||| S:745 E:756 ||| VBN
.  ||| S:756 E:758 ||| .
These  ||| S:758 E:764 ||| DT
compounds  ||| S:764 E:774 ||| NN
inhibited  ||| S:774 E:784 ||| VBD
ADP-  ||| S:784 E:789 ||| JJ
and  ||| S:789 E:793 ||| CC
collagen-induced  ||| S:793 E:810 ||| JJ
platelet  ||| S:810 E:819 ||| JJ
aggregation  ||| S:819 E:831 ||| NN
in  ||| S:831 E:834 ||| IN
a  ||| S:834 E:836 ||| DT
dose-dependent  ||| S:836 E:851 ||| JJ
manner ||| S:851 E:857 ||| NN
.  ||| S:857 E:859 ||| .
Two  ||| S:859 E:863 ||| CD
of  ||| S:863 E:866 ||| IN
these  ||| S:866 E:872 ||| DT
compounds  ||| S:872 E:882 ||| NN
were  ||| S:882 E:887 ||| VBD
shown  ||| S:887 E:893 ||| VBN
to  ||| S:893 E:896 ||| TO
be  ||| S:896 E:899 ||| VB
more  ||| S:899 E:904 ||| RBR
effective  ||| S:904 E:914 ||| JJ
inhibitors  ||| S:914 E:925 ||| NN
of  ||| S:925 E:928 ||| IN
aggregation  ||| S:928 E:940 ||| JJ
induced  ||| S:940 E:948 ||| NN
by  ||| S:948 E:951 ||| IN
ADP  ||| S:951 E:955 ||| NNP
( ||| S:955 E:956 ||| -LRB-
IC50  ||| S:956 E:961 ||| NNP
-  ||| S:961 E:963 ||| :
8-10  ||| S:963 E:968 ||| CD
μM ||| S:968 E:970 ||| NN
) ||| S:970 E:971 ||| -RRB-
,  ||| S:971 E:973 ||| ,
as  ||| S:973 E:976 ||| RB
well  ||| S:976 E:981 ||| RB
as  ||| S:981 E:984 ||| IN
collagen  ||| S:984 E:993 ||| NN
( ||| S:993 E:994 ||| -LRB-
IC50  ||| S:994 E:999 ||| NNP
-  ||| S:999 E:1001 ||| :
1.5-2.0  ||| S:1001 E:1009 ||| NNP
μM ||| S:1009 E:1011 ||| NNP
) ||| S:1011 E:1012 ||| -RRB-
.  ||| S:1012 E:1014 ||| .
